Keryx Fights Investor's Bid To Lead Kidney Drug Stock Suit
A Keryx investor seeking to lead a shareholder class action over a 2016 stock drop shouldn't head up the suit because his shares were bought through a now-defunct trust and the...To view the full article, register now.
Already a subscriber? Click here to view full article